Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for SIBO in Parkinson's Disease
NCT02470780Phase 3Completed
- Sponsor
- University of Cincinnati
- Start
- Dec 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in small intestinal bacterial overgrowth (SIBO), sponsored by University of Cincinnati. Started Dec 2015; status: completed.
02
Drugs
rifaximin
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT02470780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470780.